Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February ...

Pfizer (PFE) is one of the stocks most watched ... In the case of Pfizer, the consensus sales estimate of $17.5 billion for the current quarter points to a year-over-year change of +22.8%.

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

5. Reclaiming investment-grade rating Embraer has significantly deleveraged its balance sheet over the past three years, lowering its net debt-to-EBITDA leverage ratio to 1.3x in the third quarter ...

Here's Why MicroStrategy, Mara Holdings, and Riot Platforms Stock Were All Up Big Today MicroStrategy Stock Rose More Than 2,800% in the Past 5 Years Due to 1 Simple Decision. This Other Little ...

Here's a closer look at two names in AI that are among the dominant forces in their industries and could deliver outstanding gains to investors over the next five years. According to Palantir ...

Business Insider's personal finance team monitors the best banks and credit unions each day to help you open the right 5-year CD for you. The best 5-year CD rates far outpace the national average ...

Full Year 2024 Revenue ... 2025 Expected Net Savings from Cost Realignment: $4.5 billion by the end of 2025. Pfizer Inc (NYSE:PFE) successfully integrated the Seagen business, enhancing its ...

Considering Mahn’s stance on the year ahead, we’re here with a list of the 15 best growth stocks to buy for the next 5 years. We first sifted through online rankings, and internet lists to ...